1. Scrip
  2. >>Business
  3. >>Financing

IPO Update: 58 Drug Developers Raised $12.5bn Through Q3

With Three More In Q4, 2020 Total Reaches 61

 
• By Mandy Jackson

The average return for companies that went public in the US through the end of September was 49.4% as of 5 October. The fourth quarter started with three additional initial public offerings on 1 October.

Businessman presses button ipo Initial Public Offering diagram online network. - Image
58 IPOs through Q3 in the US grossed $12.5bn with a 49.4% average return • Source: Shutterstock

The market for biopharmaceutical initial public offerings in the US has grown more impressive in each quarter of 2020 in almost every way. There were nine IPOs in the first quarter, 20 in the second and 29 in the third quarter for a total of 58 first-time offerings by drug developers – eight more than the 50 IPOs for all of 2019. 

Also, the 29 companies that went public in the first two quarters of this year grossed $7.2bn and with 29...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By Mandy Jackson

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Finance Watch: Karyopharm Cuts Jobs In Cash Crunch; Pacira’s Layoffs Attributed To Efficiency

 
• By Mandy Jackson

Restructuring Edition: Karyopharm is reducing its workforce by 20% as it seeks alternatives to extend its cash runway, but Pacira’s production improvements created efficiency that necessitate an 8% layoff in manufacturing. Jasper, Century, Sage, Leap and Prothena also cut jobs.

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By Manas Mishra

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

More from Business

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By Mandy Jackson

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.